MORGAN STANLEY PLC/CALL/NOVO NORDISK ADR B/110/0.1/17.01.25 | Market Closed - Bid/Ask 13:50:12 01/07/2024 BST | After market 19:00:43 | |||
| 3.61 EUR | -1.37% |
|
3.805 | +5.40% |
| Current month | +27.53% | ||
| 1 month | +26.64% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 01/07/24 | 3.61 | -1.37% |
| 28/06/24 | 3.66 | -1.08% |
| 27/06/24 | 3.7 | 0.00% |
| 26/06/24 | 3.7 | -5.13% |
| 25/06/24 | 3.9 | +11.11% |
Delayed Quote Börse Stuttgart
Last update July 01, 2024 at 01:50 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Morgan Stanley |
| WKN | ME1GAN |
| ISIN | DE000ME1GAN7 |
| Date issued | 03/10/2023 |
| Strike | 110 $ |
| Maturity | 17/01/2025 (200 Days) |
| Parity | 10 : 1 |
| Emission price | 0.84 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.9 € |
|---|---|
| Lowest since issue | 0.63 € |
| Spread | 0.01 € |
| Spread % | 0.26% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,006
DKK
Average target price
950.4
DKK
Spread / Average Target
-5.49%
- Stock Market
- Warrants
- Warrant
